Odyssey Therapeutics
ODTX
58 hedge funds and large institutions have $651M invested in Odyssey Therapeutics in 2026 Q2 according to their latest regulatory filings, with 58 funds opening new positions, increasing their positions, reducing their positions, and closing their positions.
72.48% more ownership
Funds ownership: 0% → 72.48% (+72%)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Fidelity Investments
Boston,
Massachusetts
|
+$90.8M |
| 2 |
SOCM
SR One Capital Management
Wayne,
Pennsylvania
|
+$66.5M |
| 3 |
TGA
TPG GP A
Fort Worth,
Texas
|
+$64.7M |
| 4 |
LMC
Lightspeed Management Company
Menlo Park,
California
|
+$63.3M |
| 5 |
O
OrbiMed
New York
|
+$52.6M |
Top Sellers
ODTX Hedge Fund Activity: Q2 2026 in Review
58 of the 8,208 institutional investors tracked by Wall St. Rank reported a position in Odyssey Therapeutics (ODTX) for Q2 2026, worth a combined $651M.
Buyers outnumbered sellers: 58 funds opened new ODTX positions and 0 closed out — a net gain of 58 holders — while 0 added to existing stakes and 0 trimmed.
The largest buyer was Fidelity Investments, opening a new position worth an estimated $90.8M.
- 58 institutional investors held Odyssey Therapeutics (ODTX) as of Q2 2026, up from 0 in Q1 2026.
- Funds reported $651M of Odyssey Therapeutics stock for Q2 2026.
- 58 funds opened new Odyssey Therapeutics positions in Q2 2026 and 0 closed out, a net change of +58 holders.
- The largest Odyssey Therapeutics buyer in Q2 2026 was Fidelity Investments, an estimated $90.8M added.
Based on aggregated 13F filings for Q2 2026.